Sickle Cell Disease Treatment Market Trends

Sickle Cell Disease Treatment Market Trends

The prevalence of sickle cell disease is increasing worldwide and significantly impacting the global market growth. According to the data presented by the WHO, in 2022, more than 66% of the 120 million people affected by sickle cell disease were from Africa. In Africa, 1,000 children are born with the disease every day. In Africa, in 2019, approximately 38403 deaths were recorded due to sickle cell disease. The high prevalence of this disease increases the demand for treatment options like blood infusions, pharmacotherapy, and bone marrow transplants. A high prevalence of sickle cell disease is reported in Africa, the Middle East, and India. The prevalence of sickle cell disease is increasing in other geographies along with migration.
 

Due to the increasing prevalence of sickle cell disease, pharmaceutical and biotechnology companies have increased their investment in R&D in order to develop new treatment options to treat various forms of sickle cell disease, such as sickle cell anemia, hemoglobin sickle C disease, and others. The increasing initiatives by government and private organizations for the treatment of sickle cell disease will drive the market in the coming years. For instance, in 2022, according to the data published by WHO, African health ministers have launched a campaign to increase awareness, bolster prevention, and provide care to reduce the toll of sickle cell disease, which is one of the most common diseases in this region.
 

Thus, pharmaceutical companies have increased research activities for the development of new sickle cell disease treatment products. The improved healthcare infrastructure, increasing healthcare expenditures, and R&D funding will propel the growth of this market.